Use: Labeled indications
- INDICATIONS AND USAGE Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility…
Full indications and usage US FDA label
INDICATIONS AND USAGE Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride.
Contraindications
CONTRAINDICATIONS Dobutamine hydrochloride is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to Dobutamine Injection, USP solution.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Note − Do not add Dobutamine Injection, USP to 5% Sodium Bicarbonate Injection or to any other strongly alkaline solution. Because of potential physical incompatibilities, it is recommended that dobutamine hydrochloride not be mixed with other drugs in the same solution. Dobutamine hydrochloride should not be used in conjunction with other agents or diluents containing both sodium bisulfite and ethanol.
Preparation and Stability − At the time of administration, Dobutamine Injection, USP must be further diluted in an intravenous container to at least a 50 mL solution using one of the following intravenous solutions as a diluent: 5% Dextrose Injection, USP; 5% Dextrose and 0.45% Sodium Chloride Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; 10% Dextrose Injection, USP; Isolyte ® M with 5% Dextrose Injection; Lactated Ringer's Injection; 5% Dextrose in Lactated Ringer's Injection; Normosol ® -M in D5-W; 20% Osmitrol ® in Water for Injection; 0.9% Sodium Chloride Injection, USP; or Sodium Lactate Injection, USP. Intravenous solutions should be used within 24 hours.
Recommended Dosage − The rate of infusion needed to increase cardiac output usually ranged from 2.5 to 15 mcg/kg/min (see Table 1). On rare occasions, infusion rates up to 40 mcg/kg/min have been required to obtain the desired effect. Table 1 Dobutamine Infusion Rate (mL/kg/min) for Concentrations of 250, 500, and 1,000 mcg/mL Infusion Delivery Rate Drug Delivery Rate 250 mcg/mL 250 mcg/mL of diluent 500 mcg/mL 500 mcg/mL or 250 mg/500 mL of diluent 1,000 mcg/mL 1,000 mcg/mL or 250 mg/250 mL of diluent (mcg/kg/min) (mL/kg/min) (mL/kg/min) (mL/kg/min) 2.5 0.01 0.005 0.0025 5 0.02 0.01 0.005 7.5 0.03 0.015 0.0075 10 0.04 0.02 0.01 12.5 0.05 0.025 0.0125 15 0.06 0.03 0.015 Rates of infusion in mL/h for Dobutamine concentrations of 500 mcg/mL, 1,000 mcg/mL, and 2,000 mcg/mL are given in Table 2.
Table 2 Dobutamine Infusion Rate (mL/h) for 500 mcg/mL concentration Drug Delivery Rate (mcg/kg/min) Patient Body Weight (kg) 30 40 50 60 70 80 90 100 110 2.5 9 12 15 18 21 24 27 30 33 5 18 24 30 36 42 48 54 60 66 7.5 27 36 45 54 63 72 81 90 99 10 36 48 60 72 84 96 108 120 132 12.5 45 60 75 90 105 120 135 150 165 15 54 72 90 108 126 144 162 180 198 Dobutamine Infusion Rate (mL/h) for 1,000 mcg/mL concentration Drug Delivery Rate (mcg/kg/min) Patient Body Weight (kg) 30 40 50 60 70 80 90 100 110 2.5 4.5 6 7.5 9 10.5 12 13.5 15 16.5 5 9 12 15 18 21 24 27 30 33 7.5 13.5 18 22.5 27 31.5 36 40.5 45 49.5 10 18 24 30 36 42 48 54 60 66 12.5 22.5 30 37.5 45 52.5 60 67.5 75 82.5 15 27 36 45 54 63 72 81 90 99 Dobutamine Infusion Rate (mL/h) for 2000 mcg/mL concentration Drug Delivery Rate (mcg/kg/min) Patient Body Weight (kg) 30 40 50 60 70 80 90 100 110 2.5 2 3 4 4.5 5 6 7 7.5 8 5 4.5 6 7.5 9 10.5 12 13.5 15 16.5 7.5 7 9 11 13.5 16 18 20 22.5 25 10 9 12 15 18 21 24 27 30 33 12.5 11 15 19 22.5 26 30 34 37.5 41 15 13.5 18 22.5 27 31.5 36 40.5 45 49.5 The rate of administration and the duration of therapy should be adjusted according to the patient's response as determined by heart rate, presence of ectopic activity, blood pressure, urine flow, and, whenever possible, measurement of central venous or pulmonary wedge pressure and cardiac output. Concentrations of up to 5,000 mcg/mL have been administered to humans (250 mg/50 mL).
The final volume administered should be determined by the fluid requirements of the patient. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use – The safety and effectiveness of Dobutamine Injection, USP for use in pediatric patients have not been studied.
Dosage forms
Philippines
- ) solution for injection: 12.5 mg/mL (250 mg/20 mL, 12.50 mg/mL (250 mg/20 mL, 12.50 mg/mL(250 mg/20 mL, 25 mg/mL (250 mg/10 mL, 50 mg/mL (250 mg/5 mL
- Solution for injection: 12.5 mg/mL, 50 mg/mL
- Solution for intravenous infusion: 50 mg/mL
- ) solution for iv infusion: 12.5 mg/mL (250 mg/20 mL, 50 mg/mL (250 mg/5 mL
- Solution for iv infusion: 50 mg/mL
- ) solution for injection for i.v. infusion: 12.5 mg/mL (250 mg/20 mL, 50 mg/mL (250 mg/5 mL
- ) solution for i.v. injection: 50 mg/mL (250 mg/5 mL, 50 mg/mL (250 mg/mL
- Solution for i.v. infusion: 50 mg/mL
- ) concentrate solution for infusion: 50 mg/mL (250 mg/5 mL
- ) solution for iv injection: 50 mg/mL (250 mg/5 mL
and 4 more forms; see the products table.
Registered products in the Philippines
61 products registered with the Food and Drug Administration (FDA) Philippines list Dobutamine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Dobutamin (as Hydrochloride) (1 product). Products registered under these spellings are included in the table and marked.
All registered products61
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Bildobex 50Dobutamine (as Hydrochloride) | 50mg/mL Solution for Intravenous (IV) Infusion5mL USP Type I Amber glass Ampoule x 5's in plastic tray (Box of 5's) | Rx | MACKUR LABORATORIES LIMITEDIndia | Afree Pharmaceutical Distribution Corp. | DRP-11918 | May 20, 2027 | |
BlissdomineDobutamine (as hydrochloride) | 50 mg/mL Solution for Intravenous (I.V. Infusion)5 mL USP Type I Amber Glass Ampoule x 5's in plastic tray (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11918-01 | May 20, 2027 | |
CardinDobutamine (as Hydrochloride) | 50 mg/mL (250mg/5mL) Solution for Injection for I.V. InfusionUSP Type I amber coloured glass ampoule x 5 mL (Box of 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Despina Pharma Inc. | DRP-13429 | Feb 16, 2028 | |
CardiotamineDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Pharmaessence Inc.Importer: H & B Pharma International Inc. | DRP-5723-07 | Jul 18, 2028 | |
CardobDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/ 5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Ellebasy Medicale TradingImporter: H & B Pharma International Inc. | DRP-5723 | Jul 18, 2028 | |
CentraminDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Central West Medicale Inc.Importer: H & B Pharma International Inc. | DRP-5723-10 | Jul 18, 2028 | |
DELEXARDDobutamine (as hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for I.V. Injection5 mL Type 1 Clear and Colorless Glass Ampoule in PVC Tray Box of 5's | Rx | PT FERRON PAR PHARMACEUTICALSIndonesia | JMN BROTHERS PHARMA LIMITED, INC.Importer: GLORIOUS DEXA MANDAYA, INC.Trader: PT DEXA MEDICA | DRP-8132-01 | Apr 28, 2029 | |
DobexonDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Jackson Pharmaceuticals Inc.Importer: H & B Pharma International Inc. | DRP-5723-14 | Jul 18, 2028 | |
DobexonDobutamine (as hydrochloride) | 50 mg/mL Solution for Intravenous InfusionUSP Type I Amber glass ampoule x 5 mL in PVC Tray (Box of 5’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Jackson Pharmaceuticals Inc.Importer: JLT Pharma Inc. | DRP-9050-04 | Aug 26, 2031 | |
DobstalDobutamine (as hydrochloride) | 250 mg Lyophilized Powder for Intravenous InfusionUSP Type I Flint Tubular Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Aluminum Flip-off Seal x 20 mL (Box of 1's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Coporation | DRP-8356 | Sep 9, 2029 | |
DobubaxDobutamine (as hydrochloride) | 12.5 mg/mL (250 mg/20 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Vial x 20 mL (Box of 1's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9089 | May 12, 2031 | |
DobucardDobutamine (as Hydrochloride) | 12.5 mg/ml (250 mg/20 ml) Solution for injection (I.V.)20 ml USP Type I Amber Glass Vial (Box of 1's) | Rx | Ciron Drugs & Pharmaceuticals Pvt., Ltd.India | PHIL PHARMAWEALTH INC.Trader: Oboi Laboratories | DRP-4094 | Nov 20, 2027 | |
DobucardDobutamine (as hydrochloride) | 25 mg/mL (250 mg/10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule x 10 mL Box of 10's | Rx | Ciron Drugs & Pharmaceuticals Pvt., Ltd.India | Phil Pharmawealth Inc.Trader: Oboi Laboratories | DRP-3176 | Oct 5, 2029 | |
DobucoreDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Greencore Pharma Inc.Importer: H & B Pharma International Inc. | DRP-5723-04 | Jul 18, 2028 | |
DobucyDobutamine (as hydrochloride) | 50 mg/mL Solution for IV InfusionType I Clear Glass Ampoule x 5 mL (Box of 5's) | Rx | Farbe Firma Pvt. LtdIndia | Cyden Medicale Trading Inc.Importer: AMB HK Enteprises Inc. | DRP-12541-01 | Aug 30, 2027 | |
DobufreeDobutamine (as hydrochloride) | 50 mg/mL Solution for Intravenous (I.V.) Infusion5 mL USP Type I Amber Glass Ampoule x 5's in plastic tray (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution And Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-11918-02 | May 20, 2027 | |
Dobufril-12.5Dobutamine (as hydrochloride) | 12.5 mg/mL Solution for Injection (IV)USP Type III Clear glass vial x 20 mL in a plastic tray (Box of 1’s) | Rx | Cooper Pharma LimitedIndia | Bansan Pharma DistributorImporter: Ambica International Corporation | DRP-11964 | May 24, 2032 | |
Dobufril-50Dobutamine (As hydrochloride) | 50 mg/ mL Solution for Injection (IV)USP Type I amber glass ampoule x 5 mL (Box of 5's) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-11963 | May 24, 2027 | |
DobugenDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV)USP Type I Glass Ampoule x 5 mL Box of 10's | Rx | Celogen Pharma Pvt. Ltd.India | Pharmastar Int'l Trading Corp. | DR-XY43891 | Nov 18, 2029 | |
DobuheartDobutamine (as hydrochloride) | 250 mg Lyophilized Powder for Injection for I.V. InfusionUSP Type 1 flint tubular glass vial with grey bromo butyl rubber stopper and sealed with aluminum flip off seal (Box of l’s) | Rx | Indasi Lifesciences Pvt. Ltd.India | Aglobal Care, Inc. | DRP-12274 | Jul 8, 2027 | |
DobukonDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Pharmakon Pharmaceutical Inc.Importer: H & B Pharma International Inc. | DRP-5723-12 | Jul 18, 2028 | |
DobulexDobutamine (as hydrochloride) | 50 mg/mL (250 mg/5 mL) Concentrate Solution for InfusionClear Glass Ampoule x 5 mL (Box of 5's) | Rx | United Biotech Pvt. LimitedIndia | Delex Pharma International, Inc. | DRP-10473 | Nov 2, 2030 | |
DobumakDobutamine (as hydrochloride) | 50 mg/mL Solution for Injection (IV)USP Type I Amber glass ampoule x 5 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Hillcross Prime, Inc. | DRP-11965 | May 24, 2027 | |
DobumarcDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Marcburg Philippines Inc.Importer: H & B Pharma International Inc. | DRP-5723-01 | Jul 18, 2028 | |
DobumaxDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | HLM Pharmaceutical Inc.Importer: H & B Pharma International Inc. | DRP-5723-11 | Jul 18, 2028 | |
DobumaxDobutamine (as hydrochloride) | 50 mg/mL Solution for Intravenous InfusionIn a box of 1-Type I Amber Ampoule x 5 mL (Box of 5's) | Rx | Troikaa Pharmaceuticals Ltd.India | HLM Pharmaceutical Inc.Importer: Troikaa Pharmaceuticals Philippines, Inc. | DRP-10264-02 | Oct 31, 2030 | |
DobumeanDobutamine (as hydrochloride) | 12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | AGLOBAL CARE, INC. | DRP-7713 | Nov 2, 2028 | |
DobumedDobutamine (as hydrochloride) | 50 mg/mL Solution for Injection (IV)USP Type I Amber glass ampoule x 5 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Medwise, Inc.Importer: Hillcross Prime Inc. | DRP-11965-01 | May 24, 2027 | |
DobuminDobutamine (as hydrochloride) | 50 mg/mL Solution for I.V. Infusion5 mL Type I Amber Glass Ampoule with Blue Dot; 10 ampoules in a tray, each tray in a box | Rx | Kwality Pharmaceuticals Pvt. Ltd.India | Pharma-Surrey International, Inc. | DRP-6706 | Mar 24, 2031 | |
DobumineDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Mehl Pharmaceutical TradingImporter: H & B Pharma International Inc. | DRP-5723-02 | Jul 18, 2028 | |
DobunexDobutamine (as hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for IV InfusionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Swiss Parenterals Ltd.India | Endure Medical, Inc. | DR-XY38330 | Aug 4, 2028 | |
DobuproDobutamine (as hydrochloride) | 50 mg/mL Solution for Intravenous InfusionUSP Type I glass ampoule x 5 mL in PVC Tray (Box of 5’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Amediqo Phils., Inc.Importer: JLT Pharma Inc. | DRP-9050-03 | Sep 19, 2031 | |
DoburelDobutamine (as hydrochloride) | 50 mg/mL (250 mg / 5 mL) Solution for Injection for I.V. InfusionUSP Type I amber coloured glass ampoule x 5 mL (Box of 5's) | Rx | Swiss Parenterals Ltd. (Block-B)India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-13429-02 | Feb 16, 2028 | |
DoburifemDobutamine (as hydrochloride) | 50 mg / mL Solution for Injection (IV)USP Type I amber glass ampoule x 5 mL (Box of 5's) | Rx | Cooper Pharma LimitedIndia | Rifemedica CorporationImporter: Ambica International Corporation | DRP-11963-01 | May 24, 2027 | |
DoburifemDobutamine (as hydrochloride) | 50 mg/mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5 ampoules) | Rx | Makcur Laboratories LimitedIndia | Rifemedica CorporationImporter: Diafarm Inc. | DRP-13326-01 | Jan 27, 2028 | |
DoburisDobutamine (as hydrochloride) | 50 mg/mL Solution for Intravenous InfusionIn a box of 1-Type I Amber Ampoule x 5 mL Box of 5's | Rx | Troikaa Pharmaceuticals Ltd.India | Troikaa Pharmaceuticals Philippines, Inc. | DRP-10264 | Oct 31, 2030 | |
DoburxDobutamine (As Hydrochloride) | 50 mg/mL Solution for IV InfusionType I Clear Glass Ampoule x 5 mL (Box of 5's) | Rx | Farbe FirmaIndia | Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-12541 | Aug 30, 2027 | |
DobusanDobutamine (as hydrochloride) | 50 mg/mL Solution for Injection (IV)USP Type I Amber glass ampoule x 5 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime Inc. | DRP-11965-02 | May 24, 2027 | |
DobusenzDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Starpharm, Inc.Importer: H & B Pharma International Inc. | DRP-5723-05 | Jul 18, 2028 | |
DobutafresDobutamine (as hydrochloride) | 50 mg/mL Solution for IV InfusionType I amber glass ampoule x 5 mL (Box of 10 vials) | Rx | PT. Ethica Industri Farmasi (PT. Ethica)Indonesia | Fresenius Kabi Philippines Inc. | DR-XY48559 | Jan 6, 2028 | |
DOBUTAMDobutamine (as hydrochloride) | 12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | TRIPLE TACT IMPORT & EXPORT CORP.Importer: AGLOBAL CARE, INC. | DRP-7713-02 | Nov 12, 2028 | |
DobutasaphDobutamine | 12.50mg/mL(250mg/20mL) Solution for Injection (IV Infusion)Type I Flint Clear Glass Vial Sealed with Bromobutyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 20 mL (Box of 1's) | Rx | Kilitch Drugs (India) Ltd.India | Ollen Pharma Trading, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-11550 | Mar 30, 2027 | |
DOBUTAXDobutamine (as hydrochloride) | 12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC. | DRP-7713-04 | Nov 12, 2028 | |
DobutelDobutamine Hydrochloride | 50 mg/mL (250 mg/5 mL) Solution for IV Injection5 mL (Net content) in 6 mL Type I Clear Glass Vial (Box of 1's) | Rx | PT. Novell Pharmaceutical LaboratoriesIndonesia | Prosweal Healthcare Inc. | DR-XY43206 | Feb 13, 2029 | |
DobutineDobutamine (as hydrochloride) | 50 mg/mL (250 mg/ 5 mL) Solution for Injection for I.V. InfusionUSP Type I amber coloured glass ampoule x 5 mL (Box of 5’s) | Rx | Swiss Parenterals Ltd. (Block B)India | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-13429-01 | Feb 16, 2028 | |
DobutrimDobutamine (as hydrochloride) | 25 mg / mL (250 mg / 10 mL) Solution for Injection (IV)USP Type I Amber Glass Ampoule x 10 mL (Box of 10's) | Rx | Ciron Drugs & Pharmaceuticals Pvt., Ltd.India | International Apex Pharmaceutical, Inc.Importer: Phil Pharmawealth Inc. | DRP-3176-01 | Oct 5, 2029 | |
DOBUTSDobutamine (as hydrochloride) | 12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | APPLIED PHARMACEUTICAL DISTRIBUTION INCImporter: AGLOBAL CARE, INC. | DRP-7713-01 | Nov 12, 2028 | |
DobuventDobutamine | 50 mg/mL Solution for I.V. Infusion5 mL Type I Amber Glass Ampoule with Blue Dot (10 ampoules in a tray, each tray in a box) | Rx | Kwality Pharmaceuticals Ltd.India | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc | DRP-6706-01 | May 24, 2031 | |
DobuzefDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/ 5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Metro Pharma Philippines Inc.Importer: H & B Pharma International Inc. | DRP-5723-13 | Jul 18, 2028 | |
DobuzinDobutamine (as hydrochloride) | 12.5 mg/mL (250 mg/20 mL) Solution for IV InfusionUSP Type I Clear Colorless Glass Vial x 20 mL (Box of 1's) | Rx | UNIJULES LIFE SCIENCES LIMITEDIndia | GREENCORE PHARMA INC.Importer: AGLOBAL CARE, INC. | DRP-7713-03 | Nov 12, 2028 | |
DociDobutamine (as hydrochloride) | 12.50 mg/mL (250 mg/20 mL) Solution for Injection (IV Infusion)Type I Flint Clear Glass Vial Sealed with Bromobutyl Rubber Stopper And Aluminum Flip-Off Seal Cap x 20 mL (Box of 1’s) | Rx | Kilitch Drugs (India) Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ollen Pharma Trading Inc.Trader: Sapphire Lifesiences Pvt. Ltd. | DRP-11550-01 | Mar 30, 2027 | |
DotamineDobutamine (as hydrochloride) | 50 mg/mL Solution for Intravenous InfusionUSP Type I glass ampoule x 5 mL in PVC Tray (Box of 5’s) | Rx | BCWorld Pharm. Co., Ltd.Republic of Korea | Bell-Kenz Pharma Inc.Importer: JLT Pharma Inc. | DRP-9050 | Oct 31, 2030 | |
GavaminDobutamine (as Hydrochloride) | 50 mg/mL (250 mg/5 mL) Solution for Injection (IV Infusion)USP Type I Glass Ampoule x 5 mL (Box of 10's) | Rx | Myungmoon Pharmaceutical Co., Ltd.Republic of Korea | Corbridge Group Phils., Inc.Importer: H & B Pharma International Inc. | DRP-5723-06 | Jul 18, 2028 | |
ImatimDobutamine (as Hydrochloride) | 250 mg Lyophilized Powder for Injection (I.V.)USP Type I Flint Tubular Glass Vial x 20 mL (Box of 1's) | Rx | Gufic Biosciences Ltd.India | SRS Life Sciences Inc. | DR-XY40576 | Jan 27, 2027 | |
NoneDobutamine (as hydrochloride) | 12.5 mg/mL (250 mg/20 mL) Solution for Injection for I.V. InfusionUSP Type I clear glass vial with 20 mm chlorobutyl rubber stopper and 20 mm flip off seal x 20 mL (Box of 1’s) | Rx | Concept Pharmaceuticals Ltd.India | Medethix, Inc. | DRP-18471 | Jul 20, 2031 | |
NoneDobutamine (as Hydrochloride) | 12.5 mg/mL Solution for Injection (IV)Clear Glass Vial x 20mL with Rubber Stopper and Grey Flip-off Seal Box of 1’s | Rx | Hospira, Inc.USA | Importer: Pfizer, Inc. | DR-XY23120 | Jul 21, 2027 | |
NoneDobutamine (as hydrochloride) | 50 mg/mL Solution for IV InfusionUSP Type I Amber Glass Ampoule x 5 mL (Box of 5 ampoules) | Rx | Makcur Laboratories LimitedIndia | Reta DrugImporter: Diafarm Inc. | DRP-13326-02 | Jan 27, 2028 | |
50mg/mL Solution for IV InfusionUSP Type I amber glass ampoule x 5 mL (Box of 5 ampoules) | Rx | Makcur Laboratories LimitedIndia | Diafarm Inc. | DRP-13326 | Jan 27, 2028 | ||
PusogardDobutamine (as hydrochloride) | 50 mg/mL (250 mg/mL) Solution for I.V. Injection5 mL Type I clear and colorless glass ampoule in PVC Tray (Box of 5's) | Rx | PT FERRON PAR PHARMACEUTICALSIndonesia | Glorious Dexa Mandaya, Inc.Trader: PT DEXA MEDICA | DRP-8132 | Apr 28, 2029 | |
RatamineDobutamine (as hydrochloride) | 12.5 mg/mL Solution For Injection (IV Infusion)5 mL-Capacity Type 1 Amber Glass Ampoule x 3mL (Net content) (Box of 10's) | Rx | Jiangsu Ruinian Qianjin Pharmaceutical Co., Ltd.China | Raquel Abbas Pharma Inc. | DRP-19039 | Oct 21, 2031 | |
RetabuminDobutamine (as hydrochloride) | 50mg/mL Solution for Intravenous (I.V.) Infusion5 mL USP Type I Amber Glass Ampoule x 5's in plastic tray (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Reta DrugImporter: Afree Pharmaceutical Distribution Corp. | DRP-11918-03 | May 20, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS 1. Increase in Heart Rate or Blood Pressure Dobutamine hydrochloride may cause a marked increase in heart rate or blood pressure, especially systolic pressure. Approximately 10% of patients in clinical studies have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50 mm Hg or greater increase in systolic pressure.
Usually, reduction of dosage promptly reverses these effects. Because dobutamine hydrochloride facilitates atrioventricular conduction, patients with atrial fibrillation are at risk of developing rapid ventricular response. Patients with pre-existing hypertension appear to face an increased risk of developing an exaggerated pressor response. 2.
Ectopic Activity Dobutamine hydrochloride may precipitate or exacerbate ventricular ectopic activity, but it rarely has caused ventricular tachycardia. 3. Hypersensitivity Reactions suggestive of hyper-sensitivity associated with administration of Dobutamine Injection, USP, including skin rash, fever, eosinophilia, and bronchospasm, have been reported occasionally. 4.
Dobutamine Injection, USP contains sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes, in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.
Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions – Animal studies indicate that dobutamine may be ineffective if the patient has recently received a β-blocking drug. In such a case, the peripheral vascular resistance may increase. Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.
There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Increased Heart Rate, Blood Pressure, and Ventricular Ectopic Activity − A 10 to 20 mm increase in systolic blood pressure and an increase in heart rate of 5 to 15 beats/minute have been noted in most patients (see WARNINGS regarding exaggerated chronotropic and pressor effects). Approximately 5% of patients have had increased premature ventricular beats during infusions.
These effects are dose related. Hypotension − Precipitous decreases in blood pressure have occasionally been described in association with dobutamine therapy. Decreasing the dose or discontinuing the infusion typically results in rapid return of blood pressure to baseline values. In rare cases, however, intervention may be required and reversibility may not be immediate.
Reactions at Sites of Intravenous Infusion − Phlebitis has occasionally been reported. Local inflammatory changes have been described following inadvertent infiltration. Isolated cases of cutaneous necrosis (destruction of skin tissue) have been reported. Miscellaneous Uncommon Effects − The following adverse effects have been reported in 1% to 3% of patients: nausea, headache, anginal pain, nonspecific chest pain, palpitations, and shortness of breath.
Isolated cases of thrombocytopenia have been reported. Administration of dobutamine hydrochloride, like other catecholamines, can produce a mild reduction in serum potassium concentration, rarely to hypokalemic levels (see PRECAUTIONS). Longer-Term Safety − Infusions of up to 72 hours have revealed no adverse effects other than those seen with shorter infusions.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy – Teratogenic Effects − Reproduction studies performed in rats at doses up to the normal human dose (10 mcg/kg/min for 24 h, total daily dose of 14.4 mg/kg), and in rabbits at doses up to twice the normal human dose, have revealed no evidence of harm to the fetus due to dobutamine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers – It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dobutamine hydrochloride is administered to a nursing woman. If a mother requires dobutamine hydrochloride treatment, breastfeeding should be discontinued for the duration of treatment.
Pharmacokinetics
The plasma half-life of dobutamine hydrochloride in humans is 2 minutes.
In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the β receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine.
In animal studies, dobutamine hydrochloride produces less increase in heart rate and less decrease in peripheral vascular resistance for a given inotropic effect than does isoproterenol. In patients with depressed cardiac function, both dobutamine hydrochloride and isoproterenol increase the cardiac output to a similar degree.
In the case of dobutamine hydrochloride, this increase is usually not accompanied by marked increases in heart rate (although tachycardia is occasionally observed), and the cardiac stroke volume is usually increased. In contrast, isoproterenol increases the cardiac index primarily by increasing the heart rate while stroke volume changes little or declines.
Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies and in patients with atrial fibrillation. Systemic vascular resistance is usually decreased with administration of dobutamine hydrochloride. Occasionally, minimum vasoconstriction has been observed. Most clinical experience with dobutamine hydrochloride is short-term − not more than several hours in duration.
In the limited number of patients who were studied for 24, 48, and 72 hours, a persistent increase in cardiac output occurred in some, whereas output returned toward baseline values in others. The onset of action of dobutamine is within 1 to 2 minutes; however, as much as 10 minutes may be required to obtain the peak effect of a particular infusion rate.
The plasma half-life of dobutamine hydrochloride in humans is 2 minutes. The principal routes of metabolism are methylation of the catechol and conjugation. In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine. The 3-O-methyl derivative of dobutamine is inactive. Alteration of synaptic concentrations of catecholamines with either reserpine or tricyclic antidepressants does not alter the actions of dobutamine in animals, which indicates that the actions of dobutamine hydrochloride are not dependent on presynaptic mechanisms.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Dobutamine 50 mg/mL, 5 mL Ampule | ₱69.88–₱390.00Reference ₱145.85 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Dobutamine |
| PNF listing | Inj.: 50 mg/mL, 5 mL ampul (concentrate) (IV infusion) (as hydrochloride)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PNF listing | Inj.: 2 mg/mL, 250 mL D5W (pre-mixed) (IV) (as hydrochloride)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. DOBUTAMINE · Hospira, Inc. [US FDA-approved label, version 19, May 27, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89becb0c-da60-4f43-0a98-29ff7a9eca58
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .